Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

Amicus Therapeutics, Inc.

Contributing Author

Recent Articles by Amicus Therapeutics, Inc.

Feb-20	Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates GlobeNewswire
Feb-03	Amicus Therapeutics Presents New Long-term Data for both Galafold (migalastat) and POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat) at the 22nd Annual WORLDSymposium 2026 GlobeNewswire
Nov-04	Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates GlobeNewswire
Oct-31	Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025 GlobeNewswire
Oct-23	Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025 GlobeNewswire
Sep-08	New 4-Year Data for Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) Presented at ICIEM GlobeNewswire
Aug-29	Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025 GlobeNewswire
Jul-31	Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates GlobeNewswire
Jul-21	Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025 GlobeNewswire
Jun-25	Amicus Therapeutics Announces Approval of Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) in Japan GlobeNewswire
Jun-03	New Analysis of Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) Published in Muscle and Nerve GlobeNewswire
May-30	Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 GlobeNewswire
May-07	Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)